Have animal models of disease helped or hindered the drug discovery process?

Annals of the New York Academy of Sciences

Volumn 1245, Issue 1, 2011, Pages 1-2

  Hunter, Ann Jacqueline ^a  

^a OI Pharma Partners Ltd   (United Kingdom)

Author keywords

Drug discovery; Preclinical models

Indexed keywords

DRUG;

ARTICLE; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; NONHUMAN; TOXICITY TESTING; VALIDATION STUDY;

ANIMALIA;

EID: 84855210921     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06375.x     Document Type: Article

References (7)

1. Pammolli, F., L. Magazzini & M. Riccaboni 2011. The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov. 10: 428-438.
2. Paul, S.M., D.S. Mytelka, C.T. Dunwiddie, et al 2010. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 9: 203-214.
3. Kola, I & J. Landis 2004. Can the pharmaceutical industry reduce attrition rates? Nature Drug Discov. 3: 711-714.
4. Montes, J., C. Bendotti, M. Tortarolo, et al 2008. Translational research in ALS in Animal and Translational models for CNS drug discovery, Vol 2. R.A. McArthur & F. Borsini, eds.: 267-297. Academic Press.
5. Schanbel, J. 2008. Standard Model. Nature 454: 682-685.
6. Albers, G.B. 1999. Expanding the Window for Thrombolytic Therapy in Acute Stroke: The Potential Role of Acute MRI for Patient Selection. Stroke 30: 2230-2237.
7. Valenzanoa, K.J., L.G. Tafesseb, G. Leeb, et al 2005. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48: 658-672.